- Report
- July 2021
- 50 Pages
China
From €2530EUR$2,600USD£2,167GBP
- Drug Pipelines
- July 2019
- 345 Pages
Global
€21406EUR$22,000USD£18,337GBP
- Report
- February 2021
- 35 Pages
Global
€1282EUR$1,318USD£1,099GBP
- Report
- September 2022
- 120 Pages
Global
From €2432EUR$2,500USD£2,084GBP
- Drug Pipelines
- February 2023
- 127 Pages
Global
From €10698EUR$10,995USD£9,164GBP
- Report
- April 2018
Global
From €973EUR$1,000USD£834GBP
- Report
- February 2024
- 83 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- November 2021
- 600 Pages
Global
From €3892EUR$4,000USD£3,334GBP
- Report
- September 2019
Global
From €5225EUR$5,370USD£4,476GBP
- Report
- January 2022
- 137 Pages
Global
From €4378EUR$4,500USD£3,751GBP
- Book
- July 2009
- 1116 Pages
Pregabalin is a drug used to treat a variety of conditions related to the central nervous system, including epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. It is a gamma-aminobutyric acid (GABA) analog that works by binding to certain calcium channels in the brain, reducing the release of neurotransmitters that can cause pain and anxiety. Pregabalin is available in both oral and injectable forms, and is often prescribed in combination with other medications.
Pregabalin is a relatively new drug, having been approved by the US Food and Drug Administration in 2004. Since then, it has become a popular treatment option for many conditions related to the central nervous system. It is generally well-tolerated and has fewer side effects than other drugs used to treat similar conditions.
Some of the companies in the Pregabalin market include Pfizer, Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more